126
|
Hara K, Horii Y, Iijima T, Adachi I, Aihara H, Asner DM, Aushev T, Aziz T, Bakich AM, Barrett M, Bhardwaj V, Bhuyan B, Bondar A, Bonvicini G, Bozek A, Bračko M, Browder TE, Chekelian V, Chen A, Chen P, Cheon BG, Chilikin K, Cho IS, Cho K, Choi Y, Cinabro D, Dalseno J, Dingfelder J, Doležal Z, Drásal Z, Drutskoy A, Dutta D, Eidelman S, Epifanov D, Esen S, Farhat H, Frey A, Gaur V, Gabyshev N, Ganguly S, Gillard R, Goh YM, Golob B, Haba J, Hara T, Hayasaka K, Hayashii H, Higuchi T, Hoshi Y, Inami K, Ishikawa A, Itoh R, Iwasaki Y, Iwashita T, Julius T, Kang JH, Kawasaki T, Kiesling C, Kim HO, Kim JB, Kim JH, Kim KT, Kim MJ, Kim YJ, Kinoshita K, Klucar J, Ko BR, Kodyš P, Korpar S, Kouzes RT, Križan P, Krokovny P, Kronenbitter B, Kuhr T, Kumita T, Kuzmin A, Kwon YJ, Lange JS, Lee SH, Li J, Li Y, Libby J, Liu C, Liu Y, Liu ZQ, Liventsev D, Matvienko D, Miyabayashi K, Miyata H, Mizuk R, Mohanty GB, Moll A, Mori T, Muramatsu N, Nakano E, Nakao M, Nakazawa H, Natkaniec Z, Nayak M, Ng C, Nisar NK, Nishida S, Nishimura K, Nitoh O, Nozaki T, Ohshima T, Okuno S, Olsen SL, Oswald C, Ozaki H, Pakhlov P, Pakhlova G, Park CW, Park HK, Pedlar TK, Pestotnik R, Petrič M, Piilonen LE, Prim M, Röhrken M, Ryu S, Sahoo H, Sakai K, Sakai Y, Sandilya S, Santel D, Sanuki T, Sato Y, Schneider O, Schnell G, Schwanda C, Schwartz AJ, Senyo K, Seon O, Sevior ME, Shapkin M, Shen CP, Shibata TA, Shiu JG, Shwartz B, Sibidanov A, Simon F, Smerkol P, Sohn YS, Sokolov A, Solovieva E, Starič M, Sumihama M, Sumiyoshi T, Tatishvili G, Teramoto Y, Trabelsi K, Tsuboyama T, Uchida M, Uehara S, Unno Y, Uno S, Urquijo P, Ushiroda Y, Usov Y, Van Hulse C, Vanhoefer P, Varner G, Varvell KE, Vorobyev V, Wagner MN, Wang CH, Wang MZ, Wang P, Watanabe M, Watanabe Y, Williams KM, Won E, Yabsley BD, Yamamoto H, Yamashita Y, Yusa Y, Zhang ZP, Zhilich V, Zhulanov V, Zupanc A. Evidence for B- → τ- ν(τ) with a hadronic tagging method using the full data sample of Belle. PHYSICAL REVIEW LETTERS 2013; 110:131801. [PMID: 23581309 DOI: 10.1103/physrevlett.110.131801] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/16/2012] [Indexed: 06/02/2023]
Abstract
We measure the branching fraction of B- → τ- ν(τ) using the full Υ(4S) data sample containing 772×10(6) BB pairs collected with the Belle detector at the KEKB asymmetric-energy e+ e- collider. Events with BB pairs are tagged by reconstructing one of the B mesons decaying into hadronic final states, and B- → τ- ν(τ) candidates are detected in the recoil. We find evidence for B- → τ- ν(τ) with a significance of 3.0 standard deviations including systematic errors and measure a branching fraction B(B- → τ- ν(τ))=[0.72(-0.25)(+0.27)(stat)±0.11(syst)]×10(-4).
Collapse
|
127
|
Grubbs EG, Rich TA, Ng C, Bhosale PR, Jimenez C, Evans DB, Lee JE, Perrier ND. Long-term outcomes of surgical treatment for hereditary pheochromocytoma. J Am Coll Surg 2013; 216:280-9. [PMID: 23317575 DOI: 10.1016/j.jamcollsurg.2012.10.012] [Citation(s) in RCA: 64] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2012] [Revised: 10/05/2012] [Accepted: 10/15/2012] [Indexed: 02/03/2023]
Abstract
BACKGROUND The ideal surgical management of hereditary pheochromocytomas includes planning for a potential metachronous bilateral presentation and the possibility of lifelong steroid dependence if bilateral adrenalectomy is needed. An intact and viable cortical remnant after bilateral pheochromocytoma resection can eliminate the necessity for steroid dependency, but can increase the risk of pheochromocytoma recurrence. STUDY DESIGN We retrospectively reviewed outcomes of all patients with a diagnosis of hereditary pheochromocytomas treated at our tertiary cancer institution from 1962-2011, with subset analysis of patients undergoing a cortical-sparing procedure in the setting of bilateral adrenalectomy. RESULTS Of the ninety-six patients who underwent adrenalectomy for hereditary pheochromocytomas, 47 presented with bilateral disease. In 15 of the 49 patients (30%) who originally underwent unilateral adrenalectomy, pheochromocytoma developed in the contralateral gland at a median of 8.2 years (range 1 to 20 years) after the initial diagnosis. There were 4 recurrences in 55 cortical-sparing remnants (7%) and 3 recurrences in the adrenal bed after 101 intended total adrenal resections (3%) (p = 0.24). Total bilateral adrenalectomy was performed in 25 patients and acute adrenal insufficiency developed in 5 (20%) of those patients. An intended cortical-sparing adrenalectomy was performed in 39 patients and acute adrenal insufficiency developed in 1 (3%). Of these patients with adequate follow-up, 21 of 27 (78%) were steroid independent at 3-year follow-up. Sex, median age, adrenal vein preservation, metachronous adrenal resection, and bilateral cortical-sparing procedures did not predict steroid independence at 3 years. CONCLUSIONS Cortical-sparing adrenalectomy avoids long-term corticosteroid dependence in the majority of patients with hereditary pheochromocytoma with minimal risk of acute adrenal insufficiency. Recurrence occurs in approximately 7% of adrenal remnants.
Collapse
|
128
|
Sarris J, Stough C, Teschke R, Wahid ZT, Bousman CA, Murray G, Savage KM, Mouatt P, Ng C, Schweitzer I. Kava for the treatment of generalized anxiety disorder RCT: analysis of adverse reactions, liver function, addiction, and sexual effects. Phytother Res 2013; 27:1723-8. [PMID: 23348842 DOI: 10.1002/ptr.4916] [Citation(s) in RCA: 76] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2012] [Revised: 11/19/2012] [Accepted: 11/27/2012] [Indexed: 12/15/2022]
Abstract
Presently, little is known about a number issues concerning kava (Piper methysticum), including (i) whether kava has any withdrawal or addictive effects; (ii) if genetic polymorphisms of the cytochrome (CYP) P450 2D6 liver enzyme moderates any potential adverse effects; and (iii) if medicinal application of kava has any negative or beneficial effect on sexual function and experience. The study design was a 6-week, double-blind, randomized controlled trial (n = 75) involving chronic administration of kava (one tablet of kava twice per day; 120 mg of kavalactones per day, titrated in non-response to two tablets of kava twice per day; 240 mg of kavalactones) or placebo for participants with generalized anxiety disorder. Results showed no significant differences across groups for liver function tests, nor were there any significant adverse reactions that could be attributed to kava. No differences in withdrawal or addiction were found between groups. Interesting, kava significantly increased female's sexual drive compared to placebo (p = 0.040) on a sub-domain of the Arizona Sexual Experience Scale (ASEX), with no negative effects seen in males. Further, it was found that there was a highly significant correlation between ASEX reduction (improved sexual function and performance) and anxiety reduction in the whole sample.
Collapse
|
129
|
Mizuk R, Asner DM, Bondar A, Pedlar TK, Adachi I, Aihara H, Arinstein K, Aulchenko V, Aushev T, Aziz T, Bakich AM, Bay A, Belous K, Bhardwaj V, Bhuyan B, Bischofberger M, Bonvicini G, Bozek A, Bračko M, Brodzicka J, Browder TE, Chekelian V, Chen A, Chen P, Cheon BG, Chilikin K, Chistov R, Cho IS, Cho K, Choi SK, Choi Y, Dalseno J, Danilov M, Doležal Z, Drásal Z, Drutskoy A, Eidelman S, Epifanov D, Fast JE, Gaur V, Gabyshev N, Garmash A, Golob B, Haba J, Hara T, Hayasaka K, Hayashii H, Horii Y, Hoshi Y, Hou WS, Hsiung YB, Hyun HJ, Iijima T, Ishikawa A, Itoh R, Iwabuchi M, Iwasaki Y, Iwashita T, Jaegle I, Julius T, Kang JH, Kapusta P, Kawasaki T, Kim HJ, Kim HO, Kim JH, Kim KT, Kim MJ, Kim YJ, Kinoshita K, Ko BR, Koblitz S, Kodyš P, Korpar S, Kouzes RT, Križan P, Krokovny P, Kuhr T, Kumita T, Kuzmin A, Kwon YJ, Lange JS, Lee SH, Li J, Libby J, Liu C, Liu Y, Liu ZQ, Liventsev D, Louvot R, Matvienko D, McOnie S, Miyabayashi K, Miyata H, Mohanty GB, Mohapatra D, Moll A, Muramatsu N, Mussa R, Nakao M, Natkaniec Z, Ng C, Nishida S, Nishimura K, Nitoh O, Nozaki T, Ohshima T, Okuno S, Olsen SL, Onuki Y, Pakhlov P, Pakhlova G, Park CW, Park H, Pestotnik R, Petrič M, Piilonen LE, Poluektov A, Röhrken M, Sakai Y, Sandilya S, Santel D, Sanuki T, Sato Y, Schneider O, Schwanda C, Senyo K, Seon O, Sevior ME, Shapkin M, Shen CP, Shibata TA, Shiu JG, Shwartz B, Sibidanov A, Simon F, Smerkol P, Sohn YS, Sokolov A, Solovieva E, Stanič S, Starič M, Sumihama M, Sumiyoshi T, Tanida K, Tatishvili G, Teramoto Y, Tikhomirov I, Trabelsi K, Tsuboyama T, Uchida M, Uehara S, Uglov T, Unno Y, Uno S, Vanhoefer P, Varner G, Varvell KE, Vinokurova A, Vorobyev V, Wang CH, Wang MZ, Wang P, Wang XL, Watanabe M, Watanabe Y, Williams KM, Won E, Yabsley BD, Yamaoka J, Yamashita Y, Yuan CZ, Zhang ZP, Zhilich V. Evidence for the η(b)(2S) and observation of h(b)(1P)→η(b)(1S)γ and h(b)(2P)→η(b)(1S)γ. PHYSICAL REVIEW LETTERS 2012; 109:232002. [PMID: 23368184 DOI: 10.1103/physrevlett.109.232002] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/29/2012] [Indexed: 06/01/2023]
Abstract
We report the first evidence for the η(b)(2S) using the h(b)(2P)→η(b)(2S)γ transition and the first observation of the h(b)(1P)→η(b)(1S)γ and h(b)(2P)→η(b)(1S)γ transitions. The mass and width of the η(b)(1S) and η(b)(2S) are measured to be m(η(b)(1S))=(9402.4±1.5±1.8) MeV/c(2), m(η(b)(2S))=(9999.0±3.5(-1.9)(+2.8)) MeV/c(2), and Γ(η(b)(1S))=(10.8(-3.7-2.0)(+4.0+4.5)) MeV. We also update the h(b)(1P) and h(b)(2P) mass measurements. We use a 133.4 fb(-1) data sample collected at energies near the Υ(5S) resonance with the Belle detector at the KEKB asymmetric-energy e(+)e(-) collider.
Collapse
|
130
|
Stypula J, Rozanska M, Adachi I, Adamczyk K, Aihara H, Asner DM, Aushev T, Bakich AM, Bhardwaj V, Bhuyan B, Bischofberger M, Bondar A, Bonvicini G, Bozek A, Bračko M, Browder TE, Chang MC, Chang P, Chekelian V, Chen A, Chen P, Cheon BG, Chistov R, Cho IS, Cho K, Choi Y, Dalseno J, Danilov M, Dingfelder J, Doležal Z, Drásal Z, Drutskoy A, Eidelman S, Farhat H, Fast JE, Gaur V, Gabyshev N, Gillard R, Goh YM, Golob B, Haba J, Hayasaka K, Hayashii H, Horii Y, Hoshi Y, Hou WS, Hsiung YB, Hyun HJ, Iijima T, Inami K, Ishikawa A, Itoh R, Iwabuchi M, Iwasaki Y, Julius T, Kang JH, Kapusta P, Kawasaki T, Kichimi H, Kiesling C, Kim HJ, Kim JB, Kim JH, Kim KT, Kim YJ, Kinoshita K, Ko BR, Kodyš P, Korpar S, Kouzes RT, Križan P, Krokovny P, Kuhr T, Kumita T, Kuzmin A, Kwon YJ, Lee SH, Li J, Li Y, Libby J, Liu C, Liu Y, Liu ZQ, Liventsev D, Louvot R, Miyabayashi K, Miyata H, Miyazaki Y, Mizuk R, Mohanty GB, Moll A, Muramatsu N, Nakano E, Nakao M, Natkaniec Z, Ng C, Nishida S, Nishimura K, Nitoh O, Nozaki T, Ogawa S, Ohshima T, Okuno S, Olsen SL, Onuki Y, Pakhlov P, Pakhlova G, Park CW, Park H, Park HK, Pedlar TK, Pestotnik R, Petrič M, Piilonen LE, Ritter M, Röhrken M, Ryu S, Sahoo H, Sakai Y, Sandilya S, Santel D, Sanuki T, Sato Y, Schneider O, Schwanda C, Senyo K, Seon O, Sevior ME, Shapkin M, Shen CP, Shibata TA, Shiu JG, Shwartz B, Sibidanov A, Simon F, Smerkol P, Sohn YS, Sokolov A, Solovieva E, Stanič S, Starič M, Sumihama M, Sumiyoshi T, Teramoto Y, Uchida M, Uglov T, Unno Y, Uno S, Urquijo P, Usov Y, Vanhoefer P, Varner G, Varvell KE, Vorobyev V, Wang P, Wang XL, Watanabe M, Watanabe Y, Wiechczynski J, Williams KM, Won E, Yabsley BD, Yamamoto H, Yamashita Y, Zhang ZP, Zhilich V, Zhulanov V, Zupanc A. Evidence forB−→Ds+K−ℓ−ν¯ℓand search forB−→Ds*+K−ℓ−ν¯ℓ. Int J Clin Exp Med 2012. [DOI: 10.1103/physrevd.86.072007] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
131
|
Raaphorst G, Yang D, Grewaal D, Stewart D, Goel R, Ng C. Analysis of mechanisms of Cisplatin resistance in 3 pairs of human tumor-cell lines expressing normal and resistant responses to Cisplatin. Oncol Rep 2012; 2:1037-43. [PMID: 21597849 DOI: 10.3892/or.2.6.1037] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Three pairs of human tumour cell Lines each having a cisplatin sensitive parental cell line (normal) and a cisplatin resistant derivative were tested for their cisplatin responses and expression for three reputed mechanisms of resistance. In each case, the derivative cell lines showed resistance to cisplatin when treated either in exponential or plateau growth phase. For both the resistant and the normal cell line there was greater resistance to cisplatin treatment when cells were treated in exponential growth phase. Mechanisms of resistance were expressed in all three resistant variants. The cervical carcinoma resistant variant expressed higher GSH levels and lower cisplatin uptake levels but not elevated polymerase levels. The other two variant cell lines for the glioma and the lung cancer expressed all three of the mechanisms (increased GSH, decreased cisplatin uptake and increased polymerases) associated with resistance. There was no correlation to the level of resistance expressed and the number of mechanisms expressed but the change in response of the parental line to becoming a resistant variant may be related to the basal level of expression of some of the factors that are associated with resistance.
Collapse
|
132
|
Raaphorst G, Wang G, Ng C. Radiosensitization by Cisplatin treatment in Cisplatin-resistant and sensitive human ovarian-carcinoma cell-lines. Int J Oncol 2012; 7:325-30. [PMID: 21552842 DOI: 10.3892/ijo.7.2.325] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The responses of cisplatin resistant (A2780(cp)) and cisplatin sensitive (A2780) ovarian carcinoma cell lines to radiation, cisplatin and cisplatin plus radiation have been studied. The cisplatin resistant cell line showed cross resistance to radiation. When cells were exposed to 2 mu g/ml of cisplatin treatment for one hour radiosensitization was achieved. The degree of radiosensitization was treatment sequence dependent. Irradiation followed by cisplatin treatment resulted in synergistic interaction with dose modifying factors (DMFs) as high as 1.5 in the resistant line and 1.1 in the sensitive line. The reverse sequence resulted in antagonistic interaction with DMFs of 0.8 to 0.9 at the 10% survival level. At lower survival levels the interaction remained antagonistic for the resistant cell line. Increasing the cisplatin concentration to 4 mu g/ml did not increase the degree of cisplatin radiosensitization. Simultaneous treatment of irradiation during the middle of a one or two hour cisplatin treatment did not increase the degree of radiosensitization. The cisplatin resistant cell line had a much greater cisplatin radiosensitization effect than the sensitive parental cell line with maximum DMFs for the resistant cell line ranging from 0.9-1.5 and for the sensitive cell line from 0.8-1.1. These results indicate that cisplatin may be an effective radiosensitizer especially in cisplatin resistant cell lines. This effect may be related to the inhibition of repair of radiation damage which may be elevated as a mechanism of resistance in the resistant cell line.
Collapse
|
133
|
Yang FH, Zhang B, Zhou DJ, Bie L, Tom MW, Drummond DC, Nicolaides T, Mueller S, Banerjee A, Park JW, Prados MD, James DC, Gupta N, Hashizume R, Strohbehn GW, Zhou J, Fu M, Patel TR, Piepmeier JM, Saltzman WM, Xie Q, Johnson J, Bradley R, Ascierto ML, Kang L, Koeman J, Marincola FM, Briggs M, Tanner K, Vande Woude GF, Tanaka S, Klofas LK, Wakimoto H, Borger DR, Iafrate AJ, Batchelor TT, Chi AS, Madhankumar AB, Slagle-Webb B, Rizk E, Harbaugh K, Connor JR, Sarkar G, Curran GL, Jenkins RB, Kurozumi K, Ichikawa T, Onishi M, Fujii K, Ishida J, Shimazu Y, Date I, Ebsworth K, Walters MJ, Ertl LS, Wang Y, Berahovich RD, Zhang P, Powers JP, Liu SC, Al Omran R, Sullivan TJ, Jaen JC, Brown M, Schall TJ, Yusuke N, Shimizu S, Shishido-Hara Y, Shiokawa Y, Nagane M, Wang J, Sai K, Chen FR, Chen ZP, Shi Z, Zhang J, Zhang K, Han L, Chen L, Qian X, Zhang A, Wang G, Jia Z, Pu P, Kang C, Kong LY, Doucette TA, Ferguson SD, Hachem J, Yang Y, Wei J, Priebe W, Fuller GN, Qiao W, Rao G, Heimberger AB, Chen PY, Ozawa T, Drummond D, Santos R, Torre JD, Ng C, Lepe EL, Butowski N, Prados M, Bankiewicz K, James CD, Cheng Z, Gong Y, Ma Y, Muller-Knapp S, Knapp S, Wang J, Fujii K, Kurozumi K, Ichikawa T, Onishi M, Shimazu Y, Ishida J, Antonio Chiocca E, Kaur B, Date I, Yu JS, Judkowski V, Bunying A, Ji J, Li Z, Bender J, Pinilla C, Srinivasan V, Dombovy-Johnson M, Carson-Walter E, Walter K, Xu Z, Popp B, Schlesinger D, Gray L, Sheehan J, Keir ST, Friedman HS, Bigner DD, Kut C, Tyler B, McVeigh E, Li X, Herzka D, Grossman S, Lasky JL, Wang Y, Panosyan E, Meisen WH, Hardcastle J, Wojton J, Wohleb E, Alvarez-Breckenridge C, Nowicki M, Godbout J, Kaur B, Lee SY, Slagle-Webb B, Sheehan JM, Connor JR, Yin S, Kaluz S, Devi SN, de Noronha R, Nicolaou KC, Van Meir EG, Lachowicz JE, Demeule M, Che C, Tripathy S, Jarvis S, Currie JC, Regina A, Nguyen T, Castaigne JP, Zielinska-Chomej K, Mohanty C, Viktorsson K, Lewensohn R, Driscoll JJ, Alsidawi S, Warnick RE, Rixe O, deCarvalho AC, Irtenkauf S, Hasselbach L, Xin H, Mikkelsen T, Sherman JH, Siu A, Volotskova O, Keidar M, Gibo DM, Dickinson P, Robertson J, Rossmeisl J, Debinski W, Nair S, Schmittling R, Boczkowski D, Archer G, Bigner DD, Sampson JH, Mitchell DA, Miller IS, Didier S, Murray DW, Issaivanan M, Coniglio SJ, Segall JE, Al-Abed Y, Symons M, Fotovati A, Hu K, Wakimoto H, Triscott J, Bacha J, Brown DM, Dunn SE, Daniels DJ, Peterson TE, Dietz AB, Knutson GJ, Parney IF, Diaz RJ, Golbourn B, Picard D, Smith C, Huang A, Rutka J, Saito N, Fu J, Yao J, Wang S, Koul D, Yung WKA, Fu J, Koul D, Yao J, Wang S, Yuan Y, Sulman EP, Colman H, Lang FF, Yung WKA, Slat EA, Herzog ED, Rubin JB, Brown M, Carminucci AS, Amendolara B, Leung R, Lei L, Canoll P, Bruce JN, Wojton JA, Chu Z, Kwon CH, Chow LM, Palascak M, Franco R, Bourdeau T, Thornton S, Qi X, Kaur B, Kitange GJ, Mladek AC, Su D, Carlson BL, Schroeder MA, Pokorny JL, Bakken KK, Gupta SK, Decker PA, Wu W, Sarkaria JN, Colman H, Oddou MP, Mollard A, Call LT, Vakayalapati H, Warner SL, Sharma S, Bearss DJ, Chen TC, Cho H, Wang W, Hofman FM, Flores CT, Snyder D, Sanchez-Perez L, Pham C, Friedman H, Bigner DD, Sampson JH, Mitchell DA, Woolf E, Abdelwahab MG, Turner G, Preul MC, Lynch A, Rho JM, Scheck AC, Salphati L, Heffron TP, Alicke B, Barck K, Carano RA, Cheong J, Greve J, Lee LB, Nishimura M, Pang J, Plise EG, Reslan HB, Zhang X, GOuld SG, Olivero AG, Phillips HS, Zadeh G, Jalali S, Voce D, Wei Z, Shijun K, Nikolai K, Josh W, Clayton C, Bakhtiar Y, Alkins R, Burgess A, Ganguly M, Wels W, Hynynen K, Li YM, Jun H, Daniel V, Walter HA, Nakashima H, Nguyen TT, Shalkh I, Goins WF, Chiocca EA, Pyko IV, Nakada M, Furuyama N, Lei T, Hayashi Y, Kawakami K, Minamoto T, Fedulau AS, Hamada JI. LAB-EXPERIMENTAL (PRE-CLINICAL) THERAPEUTICS AND PHARMACOLOGY. Neuro Oncol 2012; 14:vi25-vi37. [PMCID: PMC3488776 DOI: 10.1093/neuonc/nos222] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2023] Open
|
134
|
Raingeard D, Ng C, Seow WY, Jinyu BC, Guest J, Steinberg P, McDougald D. Evolution from Bacteria to Mammalia of selected marker genes involved in energy metabolism and stress responses: Bioinformatic approach and applications in coral reef ecology. Comp Biochem Physiol A Mol Integr Physiol 2012. [DOI: 10.1016/j.cbpa.2012.05.087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
135
|
Ng C, Raingeard D, Chan A, Steinberg P, McDougald D. qPCR detection of hepto- and neuro- cyanotoxins in a Singaporean reservoir system. Comp Biochem Physiol A Mol Integr Physiol 2012. [DOI: 10.1016/j.cbpa.2012.05.081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
136
|
Tannir NM, Plimack E, Ng C, Tamboli P, Bekele NB, Xiao L, Smith L, Lim Z, Pagliaro L, Araujo J, Aparicio A, Matin S, Wood CG, Jonasch E. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol 2012; 62:1013-9. [PMID: 22771265 DOI: 10.1016/j.eururo.2012.06.043] [Citation(s) in RCA: 106] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2012] [Accepted: 06/20/2012] [Indexed: 01/26/2023]
Abstract
BACKGROUND Sunitinib is a standard-of-care treatment in advanced clear cell renal cell carcinoma (ccRCC). Retrospective and expanded access data suggest sunitinib has activity in advanced non-clear cell renal cell carcinoma (nccRCC). OBJECTIVE To prospectively determine the clinical efficacy and safety of sunitinib in patients with advanced nccRCC. DESIGN, SETTING, AND PARTICIPANTS This is a single-arm phase 2 trial with a two-stage design. Eligibility criteria included pathologically confirmed nccRCC or ccRCC with ≥ 20% sarcomatoid histology, performance status 0-2, measurable disease, a maximum of two prior systemic therapies, and no prior treatment with tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptors. INTERVENTION Patients received sunitinib 50mg daily on a 4-wk on, 2-wk off schedule. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS Primary end points were objective response rate (ORR) and progression-free survival (PFS). Secondary end points were safety and overall survival (OS). RESULTS AND LIMITATIONS Fifty-seven patients were eligible (nccRCC histology: papillary, 27; chromophobe, 5; unclassified, 8; collecting duct or medullary carcinoma, 6; sarcomatoid, 7; and others, 4). Median PFS for 55 evaluable patients was 2.7 mo (95% confidence interval [CI], 1.4-5.4). Two patients with chromophobe and one patient with unclassified histology had a confirmed partial response (5% ORR). Median PFS for patients with papillary histology was 1.6 mo (95% CI, 1.4-5.4). Median PFS for patients with chromophobe histology was 12.7 mo (95% CI, 8.5-NA). Median OS for all patients was 16.8 mo (95% CI, 10.7-26.3). Treatment-emergent adverse events were consistent with sunitinib's mechanism of action. The nonrandomized design and small number of patients are limitations of this study. CONCLUSIONS The differential response of chromophobe histology to sunitinib suggests a therapeutically relevant biological heterogeneity exists within nccRCC. The low ORR and short PFS with sunitinib in the other nccRCC subtypes underscore the need to enroll patients with these diverse tumors in clinical trials.
Collapse
|
137
|
Jain RK, Lee JJ, Ng C, Hong D, Gong J, Naing A, Wheler J, Kurzrock R. Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. J Clin Oncol 2012; 30:2684-90. [PMID: 22689801 DOI: 10.1200/jco.2011.36.4752] [Citation(s) in RCA: 71] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE RECIST is used to quantify tumor changes during exposure to anticancer agents. Responses are categorized as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD). Clinical trials dictate a patient's management options based on the category into which his or her response falls. However, the association between response and survival is not well studied in the early trial setting. PATIENTS AND METHODS To study the correlation between response as quantified by RECIST and overall survival (OS, the gold-standard survival outcome), we analyzed 570 participants of 24 phase I trials conducted between October 2004 and May 2009, of whom 468 had quantifiable changes in tumor size. Analyses of Kaplan-Meier estimates of OS by response and null Martingale residuals of Cox models were the primary outcome measures. All analyses are landmark analyses. RESULTS Kaplan-Meier analyses revealed strong associations between change in tumor size by RECIST and survival (P = 4.5 × 10(-6) to < 1 × 10(-8)). The relationship was found to be near-linear (R(2) = 0.75 to 0.92) and confirmed by the residual analyses. No clear inflection points were found to exist in the relationship between tumor size changes and survival. CONCLUSION RECIST quantification of response correlates with survival, validating RECIST's use in phase I trials. However, the lack of apparent boundary values in the relationship between change in tumor size and OS demonstrates the arbitrary nature of the CR/PR/SD/PD categories and questions emphasis placed on this categorization scheme. Describing tumor responses as a continuous variable may be more informative than reporting categoric responses when evaluating novel anticancer therapies.
Collapse
|
138
|
Liu ZQ, Shen CP, Yuan CZ, Iijima T, Adachi I, Aihara H, Asner DM, Aulchenko V, Aushev T, Bakich AM, Belous K, Bhardwaj V, Bhuyan B, Bischofberger M, Bondar A, Bozek A, Bračko M, Browder TE, Chang MC, Chang P, Chen A, Chen P, Cheon BG, Chistov R, Cho IS, Cho K, Choi SK, Choi Y, Dalseno J, Doležal Z, Drásal Z, Eidelman S, Epifanov D, Fast JE, Gaur V, Gabyshev N, Garmash A, Goh YM, Haba J, Hayasaka K, Hayashii H, Horii Y, Hoshi Y, Hou WS, Hsiung YB, Hyun HJ, Inami K, Ishikawa A, Itoh R, Iwabuchi M, Iwasaki Y, Iwashita T, Julius T, Kang JH, Kawasaki T, Kiesling C, Kim HJ, Kim HO, Kim JB, Kim KT, Kim MJ, Kim YJ, Ko BR, Koblitz S, Kodyš P, Korpar S, Križan P, Krokovny P, Kumita T, Kuzmin A, Kwon YJ, Lange JS, Lee SH, Li J, Li XR, Li Y, Libby J, Liu C, Liventsev D, Louvot R, Matvienko D, McOnie S, Miyabayashi K, Miyata H, Miyazaki Y, Mizuk R, Mohanty GB, Moll A, Mori T, Muramatsu N, Mussa R, Nagasaka Y, Nakano E, Nakao M, Nakazawa H, Ng C, Nishida S, Nishimura K, Nitoh O, Nozaki T, Ogawa S, Ohshima T, Okuno S, Olsen SL, Onuki Y, Pakhlov P, Pakhlova G, Park CW, Park HK, Pedlar TK, Pestotnik R, Petrič M, Piilonen LE, Ritter M, Röhrken M, Ryu S, Sahoo H, Sakai K, Sakai Y, Sanuki T, Sato Y, Schneider O, Schwanda C, Seidl R, Senyo K, Sevior ME, Shapkin M, Shebalin V, Shibata TA, Shiu JG, Shwartz B, Sibidanov A, Simon F, Smerkol P, Sohn YS, Sokolov A, Solovieva E, Stanič S, Starič M, Sumiyoshi T, Tatishvili G, Teramoto Y, Uchida M, Uehara S, Uglov T, Unno Y, Uno S, Urquijo P, Varner G, Vinokurova A, Vorobyev V, Wang CH, Wang P, Wang XL, Watanabe M, Watanabe Y, Williams KM, Won E, Yamashita Y, Yusa Y, Zhang CC, Zhang ZP, Zhilich V, Zhulanov V. Observation of new resonant structures in γγ → ωϕ, ϕϕ, and ωω. PHYSICAL REVIEW LETTERS 2012; 108:232001. [PMID: 23003948 DOI: 10.1103/physrevlett.108.232001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/25/2012] [Indexed: 06/01/2023]
Abstract
The processes γγ → ωϕ, ϕϕ, and ωω are measured using an 870 fb(-1) data sample collected with the Belle detector at the KEKB asymmetric-energy e+ e- collider. Production of vector meson pairs is clearly observed and their cross sections are measured for masses that range from threshold to 4.0 GeV. In addition to signals from well established spin-zero and spin-two charmonium states, there are resonant structures below charmonium threshold, which have not been previously observed. We report a spin-parity analysis for the new structures and determine the products of the η(c), χ(c0), and χ(c2) two-photon decay widths and branching fractions to ωϕ, ϕϕ, and ωω.
Collapse
|
139
|
Sarris J, Scholey A, Schweitzer I, Bousman C, Laporte E, Ng C, Murray G, Stough C. The acute effects of kava and oxazepam on anxiety, mood, neurocognition; and genetic correlates: a randomized, placebo-controlled, double-blind study. Hum Psychopharmacol 2012; 27:262-9. [PMID: 22311378 DOI: 10.1002/hup.2216] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/26/2011] [Accepted: 01/11/2012] [Indexed: 02/03/2023]
Abstract
RATIONALE Kava (Piper methysticum) is a psychotropic plant medicine with history of cultural and medicinal use. We conducted a study comparing the acute neurocognitive, anxiolytic, and thymoleptic effects of a medicinal dose of kava to a benzodiazepine and explored for the first time specific genetic polymorphisms, which may affect the psychotropic activity of phytomedicines or benzodiazepines. METHODS Twenty-two moderately anxious adults aged between 18 and 65 years were randomized to receive an acute dose of kava (180 mg of kavalactones), oxazepam (30 mg), and placebo 1 week apart in a crossover design trial. RESULTS After exposure to cognitive tasks, a significant interaction was revealed between conditions on State-Trait Anxiety Inventory-State anxiety (p = 0.046, partial ŋ² = 0.14). In the oxazepam condition, there was a significant reduction in anxiety (p = 0.035), whereas there was no change in anxiety in the kava condition, and there was an increase in anxiety in the placebo condition. An increase in Bond-Lader "calmness" (p = 0.002) also occurred for the oxazepam condition. Kava was found to have no negative effect on cognition, whereas a reduction in alertness (p < 0.001) occurred in the oxazepam condition. Genetic analyses provide tentative evidence that noradrenaline (SLC6A2) transporter polymorphisms may have an effect on response to kava. CONCLUSION Acute "medicinal level" doses of this particular kava cultivar in naive users do not provide anxiolytic activity, although the phytomedicine also appears to have no negative effects on cognition.
Collapse
|
140
|
Singh A, Ng C, Byron K, Osborne C, Peh A, Berk M. P-953 - Treatment biomarker: blood brain barrier (P-gp) polymorphisms predict antidepressant dose and response - a candidate gene association study. Eur Psychiatry 2012. [DOI: 10.1016/s0924-9338(12)75120-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
141
|
Haygood T, Malhotra K, Ng C, Chasen B, McEnery K, Chasen M. Migration of central lines from the superior vena cava to the azygous vein. Clin Radiol 2012; 67:49-54. [DOI: 10.1016/j.crad.2011.05.011] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2011] [Revised: 05/10/2011] [Accepted: 05/31/2011] [Indexed: 10/15/2022]
|
142
|
Lavery S, Ng C, Kyrgiou M, Farthing A. Gestational surrogacy after intra-operative oocyte collection in a hysterectomised woman diagnosed with endometrial cancer. BJOG 2011; 118:1669-71. [PMID: 21967041 DOI: 10.1111/j.1471-0528.2011.03145.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
143
|
Chang Y, Hsu K, Chen L, Wu C, Chen J, Ng C. 289 A Comparison Between the 4-level and 5-level Taiwan Pediatric Triage System in Predicting Resource Utilization in the Emergency Department. Ann Emerg Med 2011. [DOI: 10.1016/j.annemergmed.2011.06.319] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
144
|
Bhardwaj V, Trabelsi K, Singh JB, Choi SK, Olsen SL, Adachi I, Adamczyk K, Asner DM, Aulchenko V, Aushev T, Aziz T, Bakich AM, Barberio E, Belous K, Bhuyan B, Bischofberger M, Bondar A, Bračko M, Brodzicka J, Browder TE, Chen A, Chen P, Cheon BG, Cho K, Choi Y, Dalseno J, Doležal Z, Eidelman S, Epifanov D, Gaur V, Gabyshev N, Golob B, Haba J, Hayasaka K, Hayashii H, Horii Y, Hoshi Y, Hou WS, Hsiung YB, Hyun HJ, Iijima T, Inami K, Ishikawa A, Iwabuchi M, Iwasaki Y, Iwashita T, Joshi NJ, Julius T, Kang JH, Kawasaki T, Kiesling C, Kim HO, Kim JB, Kim JH, Kim KT, Kim MJ, Kim SK, Kim YJ, Kinoshita K, Ko BR, Kobayashi N, Korpar S, Križan P, Kumar R, Kumita T, Kuzmin A, Kwon YJ, Lange JS, Lee MJ, Lee SH, Li Y, Libby J, Lim CL, Liventsev D, Louvot R, Matvienko D, McOnie S, Miyabayashi K, Miyata H, Miyazaki Y, Mizuk R, Mohanty GB, Mussa R, Nakano E, Nakao M, Nakazawa H, Natkaniec Z, Ng C, Nishida S, Nitoh O, Nozaki T, Ohshima T, Okuno S, Onuki Y, Pakhlova G, Park CW, Park HK, Pestotnik R, Petrič M, Piilonen LE, Röhrken M, Sahoo H, Sakai K, Sakai Y, Sanuki T, Schneider O, Schwanda C, Seon O, Shapkin M, Shebalin V, Shibata TA, Shiu JG, Shwartz B, Smerkol P, Sohn YS, Sokolov A, Solovieva E, Stanič S, Starič M, Sumiyoshi T, Tatishvili G, Teramoto Y, Uchida M, Uehara S, Uglov T, Unno Y, Uno S, Usov Y, Varner G, Vossen A, Wang XL, Watanabe M, Watanabe Y, Williams KM, Yabsley BD, Yamashita Y, Yuan CZ, Zhang CC, Zhang ZP, Zhilich V, Zhou P, Zhulanov V, Zupanc A. Observation of X(3872)→J/ψγ and search for X(3872)→ψ'γ in B decays. PHYSICAL REVIEW LETTERS 2011; 107:091803. [PMID: 21929226 DOI: 10.1103/physrevlett.107.091803] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/02/2011] [Indexed: 05/31/2023]
Abstract
We report a study of B→(J/ψγ)K and B→(ψ'γ)K decay modes using 772×10⁶ B ̅B events collected at the Υ(4S) resonance with the Belle detector at the KEKB energy-asymmetric e(+)e(-) collider. We observe X(3872)→J/ψγ and report the first evidence for χ(c2)→J/ψγ in B→(X_{c ̅cγ)K decays, while in a search for X(3872)→ψ'γ no significant signal is found. We measure the branching fractions, B(B(±)→X(3872)K(±))B(X(3872)→J/ψγ)=(1.78(-0.44)(+0.48)±0.12)×10(-6), B(B(±)→χ(c2)K(±))=(1.11(-0.34)(+0.36)±0.09)×10(-5), B(B(±)→X(3872)K(±))B(X(3872)→ψ'γ)<3.45×10⁶ (upper limit at 90% C.L.), and also provide upper limits for other searches.
Collapse
|
145
|
Matrana MR, Ng C, Rao P, Lim ZD, Tannir NM. Chromophobe renal cell carcinoma with sarcomatoid dedifferentiation treated with pazopanib: a case report. Clin Genitourin Cancer 2011; 9:137-9. [PMID: 21831725 DOI: 10.1016/j.clgc.2011.06.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2011] [Accepted: 06/17/2011] [Indexed: 10/17/2022]
|
146
|
Naing A, Kurzrock R, Burger A, Gupta S, Lei X, Busaidy N, Hong D, Chen HX, Doyle LA, Heilbrun LK, Rohren E, Ng C, Chandhasin C, LoRusso P. Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin Cancer Res 2011; 17:6052-60. [PMID: 21750201 DOI: 10.1158/1078-0432.ccr-10-2979] [Citation(s) in RCA: 99] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
PURPOSE Mammalian target of rapamycin (mTOR) inhibitors mediate AKT activation through a type 1 insulin-like growth factor receptor (IGF-1R)-dependent mechanism. Combining the mTOR inhibitor temsirolimus with cixutumumab, a fully human immunoglobulin G1 monoclonal antibody directed against IGF-1R, was expected to enhance mTOR-targeted anticancer activity by modulating resistance to mTOR inhibition. The objectives of this phase I study were to evaluate the tolerability and activity of temsirolimus and cixutumumab. EXPERIMENTAL DESIGN Patients in sequential cohorts ("3 + 3" design) received escalating doses of temsirolimus with cixutumumab weekly for 28 days. At the maximum tolerated dose (MTD), 21 patients were randomized into three separate drug sequence treatment groups for serial blood draws and 2[18F]fluoro-2-deoxy-d-glucose positron emission tomography combined with X-ray computed tomography (FDG-PET/CT) scans for pharmacodynamic analyses (PD). RESULTS Forty-two patients with advanced cancer (19 male/23 female, median age = 53, median number of prior therapies = 4) were enrolled. MTD was reached at cixutumumab, 6 mg/kg IV and temsirolimus, 25 mg IV. Dose-limiting toxicities included grade 3 mucositis, febrile neutropenia, and grade 4 thrombocytopenia. The most frequent toxicities were hypercholesterolemia, hypertriglyceridemia, hyperglycemia, thrombocytopenia, and mucositis. Tumor reduction was observed in 2 of 3 patients with Ewing's sarcoma and in 4 of 10 patients with adrenocortical carcinoma. PD data suggest that cixutumumab alone or combined with temsirolimus increased plasma IGF-1 and IGF binding protein 3. FDG-PET/CT showed the odds of achieving stable disease decreased by 58% (P = 0.1213) with a one-unit increase in absolute change of standard uptake value from baseline to day 3. CONCLUSIONS Temsirolimus combined with cixutumumab was well tolerated. We are currently enrolling expansion cohorts at the MTD for Ewing's sarcoma and adrenocortical carcinoma.
Collapse
|
147
|
Camacho LH, Garcia S, Panchal AM, Lim J, Hong DS, Ng C, Madoff DC, Fu S, Gayed I, Kurzrock R. Exploratory study of hepatic arterial infusion oxaliplatin with systemic 5-fluorouracil/bevacizumab in patients with refractory solid tumor and extensive liver metastases. Clin Colorectal Cancer 2011; 9:311-4. [PMID: 21208846 DOI: 10.3816/ccc.2010.n.045] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
PURPOSE This pilot clinical trial explored the feasibility, safety, and efficacy of regional hepatic therapy combined with systemic anticancer agents in patients with refractory solid tumors and extensive unresectable liver involvement, including those with compromised hepatic function. PATIENTS AND METHODS Six patients with colorectal (N = 3), ovarian (N = 2), and hepatocellular carcinoma (N = 1) received intra-arterial hepatic oxaliplatin followed by intravenous 5-fluorouracil, leucovorin, and bevacizumab every 2 weeks until disease progression. All had extensive liver metastases; four had elevated baseline serum total bilirubin. Median total bilirubin was 2.8 mg/dL (range, 0.2-5.2 mg/dL). Median Child-Pugh score was 7 (range, 5-10). RESULTS Thirty treatments were delivered (2-7 per patient). Median age of patients was 57 years (range, 25-69 years). Three patients (1 with colorectal, 1 with hepatocellular, and 1 with ovarian cancer) attained partial responses. Two had failed previous oxaliplatin and cisplatin treatment. Some with elevated bilirubin at baseline had a significant drop in bilirubin with treatment (bilirubin 5.2 → 1 mg/dL, 4.8 → 1.1 mg/dL, and 5.2 → 1.8 mg/dL). The regimen was generally well tolerated; the most common side effects were grade 1 fatigue, anorexia, and/or hypertension. One patient died of enzyme-linked, immunoassay-confirmed, heparin-induced thrombocytopenia during the sixth cycle of therapy. CONCLUSION At doses tested, this regimen was safe and demonstrated antitumor activity in patients with advanced refractory malignancies involving the liver, including those with hepatic insufficiency. Further study is warranted.
Collapse
|
148
|
Dickson PV, Jimenez C, Chisholm GB, Kennamer DL, Ng C, Grubbs EG, Evans DB, Lee JE, Perrier ND. Posterior retroperitoneoscopic adrenalectomy: a contemporary American experience. J Am Coll Surg 2011; 212:659-65; discussion 665-7. [PMID: 21463807 DOI: 10.1016/j.jamcollsurg.2010.12.023] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2010] [Accepted: 12/15/2010] [Indexed: 02/08/2023]
Abstract
BACKGROUND Posterior retroperitoneoscopic adrenalectomy (PRA) is an excellent surgical option for adrenal gland removal. The operation requires that surgeons learn a new approach with few similarities to anterior adrenalectomy. This study reports a large series of PRAs incorporated into surgical care using a team-model approach. STUDY DESIGN The prospective endocrine surgery database was queried to identify patients who underwent PRA during a recent 4-year period. Demographic, operative, and pathologic data were recorded. The authors' initial experiences with PRA (group 1) are compared with our contemporary experience (group 2). RESULTS One hundred and eighteen PRAs were successfully performed (100 unilateral and 9 bilateral). Indications were pheochromocytoma in 21 patients, Cushing's syndrome or Cushing's disease in 22 patients, aldosteronoma in 22 patients, virilizing tumor in 3 patients, isolated metastasis in 28 patients, and nonfunctional mass in 19 patients. Forty-eight percent of patients had undergone earlier abdominal surgery. Forty-eight percent were obese (body mass index [calculated as kg/m(2)] ≥30). No significant differences were found in operative time (110 versus 118 minutes, p = 0.30), tumor size (2.59 versus 2.85 cm, p = 0.44), or body mass index (29.63 versus 29.93, p = 0.82) between groups 1 and 2. Both complications (15.9% versus 7.7%, p = 0.29) and conversion rates (9.5% versus 1.9%, p = 0.19) were lower in group 2, although this was not statistically significant. CONCLUSIONS PRA is a technique safely performed for a variety of adrenal lesions, is ideal for patients who have undergone earlier abdominal surgery, and is feasible in obese patients. Proficiency can be obtained during a short period, leading to low conversion and complication rates. This technique should be incorporated into the armamentarium of the endocrine surgeon. A team approach to learning new surgical techniques is effective.
Collapse
|
149
|
Richey SL, Ng C, Lim ZD, Jonasch E, Tannir NM. Durable remission of metastatic renal cell carcinoma with gemcitabine and capecitabine after failure of targeted therapy. J Clin Oncol 2011; 29:e203-5. [PMID: 21172884 PMCID: PMC4468428 DOI: 10.1200/jco.2010.31.6091] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
|
150
|
Kwok W, Wong R, Ng C, Yeung E, Hsin M, Wan I, Wan S, Underwood M. A003 Changing Risk Profiles of Patients with Atherosclerosis Referred for Surgical Revascularization. Int J Cardiol 2011. [DOI: 10.1016/s0167-5273(11)70010-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|